Results 71 to 80 of about 12,319,760 (359)

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Inhibition of DPP4 activity in humans establishes its in vivo role in CXCL10 post‐translational modification: prospective placebo‐controlled clinical studies

EMBO Molecular Medicine, 2016
Biochemical experiments, animal models, and observational studies in humans all support a role of dipeptidyl peptidase 4 (DPP4) in the N‐terminal truncation of CXCL10, which results in the generation of an antagonist form of the chemokine that limits T ...
Jérémie Decalf, Kristin V Tarbell, Armanda Casrouge, Jeffrey D Price, Grace Linder, Estelle Mottez, Philippe Sultanik, Vincent Mallet, Stanislas Pol, Darragh Duffy, Matthew L Albert   +10 more
doaj   +1 more source

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

Frontiers in Immunology, 2018
Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many different tumor types. Superior overall survival over chemotherapy has been reported in various metastatic cancers.
Wouter W. van Willigen, M. Bloemendal, W. Gerritsen, G. Schreibelt, I. D. de Vries, K. Bol   +5 more
semanticscholar   +1 more source

pH-Degradable mannosylated nanogels for dendritic cell targeting [PDF]

, 2016
We report on the design of glycosylated nanogels via core-cross linking of amphiphilic non-water-soluble block copolymers composed of an acetylated glycosylated block and a pentafluorophenyl (PFP) activated ester block prepared by reversible addition ...
Ayres, Neil, De Coen, Ruben, De Geest, Bruno, De Koker, Stefaan, Grooten, Johan, Louage, Benoit, Lybaert, Lien, Nuhn, Lutz, Risseeuw, Martijn, Taylor, Leeanne, Udhayakumar, Vimal Kumar, Van Calenbergh, Serge, Vanparijs, Nane   +12 more
core   +2 more sources

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Dissecting T Cell Contraction In Vivo Using a Genetically Encoded Reporter of Apoptosis

Cell Reports, 2012
Contraction is a critical phase of immunity whereby the vast majority of effector T cells die by apoptosis, sparing a population of long-lived memory cells.
Kym R. Garrod, Hélène D. Moreau, Zacarias Garcia, Fabrice Lemaître, Isabelle Bouvier, Matthew L. Albert, Philippe Bousso   +6 more
doaj   +1 more source

To respond or not to respond - a personal perspective of intestinal tolerance [PDF]

, 2018
For many years, the intestine was one of the poor relations of the immunology world, being a realm inhabited mostly by specialists and those interested in unusual phenomena.
A Besredka, A Goubier, A Iwasaki, A Konrad, A Limmer, A Mortha, A Vaillant, AJ MacPherson, Allan McI. Mowat, AM Mowat, B Cassani, B Dubois, B Jabri, B Johansson-Lindbom, C Asseman, C Berlin, C Siewert, C Varol, CC Bain, CC Bain, CL Scott, CL Scott, CM Sun, CR Mackay, CR Stokes, D Esterhazy, D Fina, D Mucida, D Sichien, DP McGovern, DS Shouval, E Jaensson, E Jaensson-Gyllenback, E Mazzini, E Zigmond, EJ Kunkel, EM Nilsen, EM Nilsen, F Broere, F Ginhoux, F Hauet-Broere, F Powrie, FG Chirdo, G Lack, G Matteoli, G Mayrhofer, G Monteleone, GG MacPherson, H Arentz-Hanson, H Fukaura, H Tlaskalova, HG Wells, HL Klaasen, HL Weiner, HL Weiner, I Vicente-Suarez, ID Iliev, II Ivanov, J Farache, J Farache, JA Mattingly, JA Mattingly, JB Sun, JF Heremans, JH Niess, JL Coombes, JL Gowans, JL Viney, JM Blander, JP Hugot, JR Battisto, JR McDole, K Atarashi, K Atarashi, K Lahl, K Nagatani, K Takeda, KG McDonald, KM Luda, KM Smith, KP Zimmer, KS Kim, L Maiuri, L Maiuri, L Saurer, LA Hanson, LA Reynolds, LA Waaij van der, LM Sollid, M Boucard-Jourdin, M Butler, M Chieppa, M Karlsson, M Murai, M Rescigno, M Rimoldi, M Tsuji, M Yoshida, MH Jang, MH Jang, MO Li, MR Hepworth, MR Karlsson, MW Chase, N Korneychuk, N Satoh-Takayama, N Sudo, O Schulz, P Brandtzaeg, P Morrissey, PA Crabbe, PB Carter, PM Smith, R Bouziat, R Kuhn, R Zeng, R Zeng, RE Araya, RL Owen, RW DePaolo, S Hue, S Husby, S Husby, S Kawamoto, S Strobel, S Strobel, S Veenbergen, S Wilks, SI Hammerschmidt, SK Mazmanian, SV Kim, T Joeris, T Worbs, TB Tomasi Jr, TL Denning, U Hadis, V Cerovic, V Gaboriau-Routhiau, Y Chen, Y Cong, Y Ogura, ZM Falchuk, Ø Molberg   +142 more
core   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Chimerism after organ transplantation [PDF]

, 1997
Recent evidence suggests that passenger leukocytes migrate after organ transplantation and produce persistent chimerism, which is essential for sustained survival of the allograft.
Demetris, AJ, Fung, JJ, Murase, N, Rao, AS, Starzl, TE, Thomson, AW, Trucco, M   +6 more
core   +1 more source

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology, EarlyView.
Von Locquenghien et al. report that MiTE‐144, a triggering receptor expressed on myeloid cells 2 (TREM2) blocking antibody fused to interleukin‐2 (IL2) variant with tumour microenvironment restricted activation, demonstrates superior anticancer efficiency in a preclinical setting.
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
wiley   +1 more source